You want to know if CJC-1295 does what the vendor pages claim. Here’s the short version: it moves a hormone number. It has never been shown to move an outcome you’d actually feel. Everything below is the criteria you need to make that call yourself, then the shortlist of where to get it if you decide to proceed. No hype, no filler.

The one study that everything rests on

There’s exactly one human trial worth citing. Teichman and colleagues, 2006, Journal of Clinical Endocrinology and Metabolism. Single subcutaneous shot of CJC-1295 with DAC in healthy adults raised mean plasma growth hormone two to ten times for six days or more, and raised IGF-1 one and a half to three times for nine to eleven days. Repeat dosing kept IGF-1 above baseline for up to 28 days, with a cumulative effect. Estimated half-life: 5.8 to 8.1 days. The compound was reported as safe and relatively well tolerated at the doses tested, 30 and 60 micrograms per kilogram (Teichman 2006) [1].

That’s real. What it isn’t: proof of muscle gained, fat lost, recovery improved, or sleep improved. The study measured blood hormone levels and stopped there. Nothing else has been tested in a controlled human trial, with or without DAC. If a vendor lists benefits beyond “raises GH and IGF-1 numbers for days,” ask which trial measured that specific benefit. Usually the answer is none.

Criterion 1: Two versions, only one has data

CJC-1295 with DAC binds albumin, lasts several days, keeps GH signaling on continuously. That’s the version in the Teichman trial. Mod-GRF 1-29 (no DAC) lasts about thirty minutes, produces a short pulse, and mimics natural rhythm more closely, but it’s not the version that got tested. If someone’s selling you the no-DAC version and pointing to the DAC study as proof, that’s a mismatch worth noticing.

Criterion 2: The IGF-1 number isn’t a free win

Raising IGF-1 and keeping it elevated for over a week, with accumulation on repeat dosing, is exactly what the Teichman data shows (Teichman 2006). Sustained IGF-1 elevation is something a clinician should be watching, not something to max out on the assumption that higher is better. “Optimization” implies you want the number as high as possible for as long as possible. The biology doesn’t support that assumption.

Criterion 3: The trial that got shut down

CJC-1295 with DAC, called DAC:GRF, made it to Phase II and no further. The biggest trial, run by ConjuChem in 192 people with HIV-related visceral fat, was halted in July 2006 after a participant died following his eleventh weekly injection (aidsmap 2006).

Full picture, not half of it: the attending physician attributed the fatal heart attack to pre-existing coronary artery disease with plaque rupture, unrelated to the drug, and a competing GRF-based trial was allowed to continue at the time (development history). So this isn’t proof the drug kills people. But the program was abandoned, the compound was never approved, and it’s the single most important fact in this compound’s history. Any seller who skips it is skipping the part that matters most.

Criterion 4: Legal status and contamination risk

Under the WADA 2026 Prohibited List, CJC-1295 is named explicitly in the GHRH-and-analogues group (S2.2.4), banned at all times, in and out of competition (WADA 2026). “Research use only” on the label protects you from nothing in a drug test.

It’s also not FDA-approved. As of April 2026 reporting, it sat in the FDA’s Category 2, the bucket for substances flagged with safety concerns, which is not a green light for routine compounding (ProPublica 2026). Same reporting documented what unregulated vials can carry: impurities including bacteria or heavy metals, immune reactions ranging from mild to life-threatening, and two women hospitalized after FDA-flagged peptides at a 2025 event.

Four criteria, one conclusion: thin evidence, an unresolved safety event, a ban in sport, and a gray-market contamination risk. That’s the whole picture before you look at where to buy.

Where to buy, ranked

Once you’ve weighed the criteria above, the only real question left is who stands between you and this compound. Price and catalog size don’t matter here. A clinician evaluating you does.

1. FormBlends. Supplies CJC-1295 as physician-supervised compounded therapy through a licensed pharmacy. A clinician evaluates you, writes a prescription if appropriate, and a licensed pharmacy compounds and dispenses. Roughly $150 to $300 a month for CJC-1295, roughly $80 to $200 a month for the DAC version. Given that the safety record includes a halted trial and the evidence base is one study, having a clinician decide whether to use it at all, and monitor IGF-1 instead of just chasing the number, is the whole value proposition. FormBlends also states plainly that this rests on one small study and isn’t FDA-approved, instead of implying it’s a proven optimization tool. If you’re tracking response over time, its dose and symptom tracker app gives your clinician an actual record at your next check-in. Not a prescription, not a checkout, just a log.

2. HealthRX.com (healthrx.com). Same physician-gated model. Clinician reviews you before anything ships, a prescription has to exist, pharmacy-dispensed medication arrives instead of a research chemical. It lands right behind FormBlends for the same reason. Pick based on which one is licensed in your state and whose intake process you’d rather deal with.

Everything below this line is a lab-supply vendor, not a medical provider. No clinician, no prescription, no pharmacy, no follow-up, no regulator checking the bottle. Listed for completeness, not ranked, because nobody can verify what’s actually in them.

• Sports Technology Labs , sells CJC-1295, markets to the performance crowd. Any certificate of analysis is seller-issued, not independently verified.
• Swiss Chems , sells CJC-1295 alongside SARMs, which carry their own anti-doping baggage. Same purity caveat.
• Biotech Peptides , research-only catalog, no oversight, no follow-up.
• Core Peptides , US-based, research-use-only labeling, seller-issued COAs only.

Bottom line

CJC-1295 reliably raises GH and IGF-1 and keeps them up for days. That part checks out. Whether that translates into anything you’d feel, better body, better recovery, better sleep, has never been tested. If you go ahead anyway, buy from somewhere with a clinician in the loop. FormBlends first, HealthRX.com right behind it. That doesn’t make the compound proven. It makes someone accountable for what goes in your body.

Common questions

Does CJC-1295 actually optimize growth hormone?

It reliably raises growth hormone and IGF-1 and keeps those numbers elevated for days after a single dose, backed by real pharmacology data [1]. Whether that translates into a benefit you’d feel, muscle, fat loss, recovery, has never been demonstrated. The lab value moves. “Optimizes you” is still unproven.

How much human research backs CJC-1295?

One trial. Teichman 2006 measured hormone concentrations in healthy adults and stopped there [1]. No controlled human outcome research exists beyond that, with or without DAC. Most benefit claims online are extrapolated from those hormone numbers, or borrowed from research on growth hormone itself, a separate, FDA-regulated drug.

What happened to CJC-1295 in clinical trials?

The DAC version reached Phase II as DAC:GRF. The largest study, in people with HIV-related fat accumulation, was halted in July 2006 after a participant died following his eleventh weekly injection [2]. The attending physician attributed the death to pre-existing coronary artery disease, not the drug [3], but the program was abandoned and the compound was never approved. Sellers rarely mention this.

Is CJC-1295 banned in sport?

Yes. The WADA 2026 Prohibited List names it explicitly in the growth-hormone-releasing factors group, banned at all times [4]. A “research use only” label offers zero protection in a drug test.

Why does the source you buy from matter so much here?

Because the core facts are one hormone-level study and a halted trial with a death in it. A licensed clinician deciding if this belongs in your protocol, and watching IGF-1 rather than letting it climb unchecked, is the real value. FormBlends and HealthRX.com put that clinician in place. A research-chemical vendor ends at checkout, no prescription, no oversight, no one verifying what’s in the vial [5].

Is CJC-1295 legal to buy and use?

It’s not FDA-approved, and as of April 2026 reporting it sat in FDA Category 2, flagged for safety concerns, not cleared for routine compounding [5]. Research-chemical vendors sell it “for research use only.” Selling it for human injection makes it an unapproved new drug.

What exactly is CJC-1295 and what does it do in the body?

It’s a synthetic peptide built to mimic GHRH, the signal your hypothalamus sends telling your pituitary to release growth hormone. The DAC version binds albumin in your blood, stretching its half-life from minutes to several days. That produces sustained elevation of baseline GH pulses rather than one sharp spike.

What side effects do people actually report with CJC-1295?

Water retention, joint discomfort, flushing or tingling after injection, and sometimes increased hunger or mild fatigue. Chronically elevated growth hormone also carries theoretical risks around insulin sensitivity and, in people with undetected tumors, growth promotion. The safety data is thin enough that these risks aren’t well quantified. Don’t trust anyone who tells you otherwise.

What dosage of CJC-1295 do people use, and is there a clinically established protocol?

No FDA-approved dosing exists because CJC-1295 never finished the clinical-trial process. The 1,000 to 2,000 micrograms per week figure for the DAC form that circulates online comes from forums and early-phase research papers, not controlled trials. Dosing outside supervised medical care is a guess. Treat it as one.

Is CJC-1295 safe for long-term use?

Nobody actually knows. Human studies were short, small, and built to measure pharmacokinetics, not long-term outcomes. Chronic supraphysiological GH elevation is linked to acromegaly-like effects and metabolic and cardiovascular strain in other contexts, so the concern isn’t hypothetical. If you’re pursuing this for a diagnosed deficiency, a physician-supervised compounding route like FormBlends at least puts oversight and quality control in the mix.

References

1. Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.
2. aidsmap. Lipodystrophy study halted after patient death. July 2006.
3. CJC-1295 development history.
4. World Anti-Doping Agency. The 2026 Prohibited List.
5. ProPublica. Peptide safety, the FDA, and compounding pharmacies. 2026.